Activating mutations in RRAS underlie a phenotype within the RASopathy spectrum and contribute to leukaemogenesis.
СтатьяПоддержка NIH: внешняя программаПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Flex Elisabetta, Jaiswal Mamta, Pantaleoni Francesca, Martinelli Simone, Strullu Marion, Fansa Eyad K, Caye Aurélie, De Luca Alessandro, Lepri Francesca, Dvorsky Radovan, Pannone Luca, Paolacci Stefano, Zhang Si-Cai, Fodale Valentina, Bocchinfuso Gianfranco, Rossi Cesare, Burkitt-Wright Emma M M, Farrotti Andrea, Stellacci Emilia, Cecchetti Serena, Ferese Rosangela, Bottero Lisabianca, Castro Silvana, Fenneteau Odile, Brethon Benoît, Sanchez Massimo, Roberts Amy E, Yntema Helger G, Van Der Burgt Ineke, Cianci Paola, Bondeson Marie-Louise, Cristina Digilio Maria, Zampino Giuseppe, Kerr Bronwyn, Aoki Yoko, Loh Mignon L, Palleschi Antonio, Di Schiavi Elia, Carè Alessandra, Selicorni Angelo, Dallapiccola Bruno, Cirstea Ion C, Stella Lorenzo, Zenker Martin, Gelb Bruce D, Cavé Hélène, Ahmadian Mohammad R, Tartaglia Marco
Аннотация
RASopathies, a family of disorders characterized by cardiac defects, defective growth, facial dysmorphism, variable cognitive deficits and predisposition to certain malignancies, are caused by constitutional dysregulation of RAS signalling predominantly through the RAF/MEK/ERK (MAPK) cascade. We report on two germline mutations (p.Gly39dup and p.Val55Met) in RRAS, a gene encoding a small monomeric GTPase controlling cell adhesion, spreading and migration, underlying a rare (2 subjects among 504 individuals analysed) and variable phenotype with features partially overlapping Noonan syndrome, the most common RASopathy. We also identified somatic RRAS mutations (p.Gly39dup and p.Gln87Leu) in 2 of 110 cases of non-syndromic juvenile myelomonocytic leukaemia, a childhood myeloproliferative/myelodysplastic disease caused by upregulated RAS signalling, defining an atypical form of this haematological disorder rapidly progressing to acute myeloid leukaemia. Two of the three identified mutations affected known oncogenic hotspots of RAS genes and conferred variably enhanced RRAS function and stimulus-dependent MAPK activation. Expression of an RRAS mutant homolog in Caenorhabditis elegans enhanced RAS signalling and engendered protruding vulva, a phenotype previously linked to the RASopathy-causing SHOC2(S2G) mutant. Overall, these findings provide evidence of a functional link between RRAS and MAPK signalling and reveal an unpredicted role of enhanced RRAS function in human disease.